E-mail: ivan.spicka@lf1.cuni.cz
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikované knihy
Publikovaná abstrakta
- A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM)
- Bortezomib (Velcade) in the Treatment of Relapsed or Refractory Multiple Myeloma: Analysis of Safety and Efficacy of Bortezomib From Registry of Monoclonal Gammopathy of Czech Myeloma Group
- BORTEZOMIB AS A SINGLE AGENT IN REFRACTORY/RELAPSED MULTIPLE MYELOMA RESULTS OF CZECH MYELOMA GROUP (CMG)
- Bortezomib Plus Melphalan–Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan–Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years Follow-up and Extensive Subsequent Therapy Use
- Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus Cyclophosphamide as Induction Therapy in Previously Untreated Multiple Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial
- Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study
- Consolidation Therapy Based on Conventional Chemotherapy and Corticoids Do Not Provide Therapeutic Advantage for Newly Diagnosed Patients after Autologous Transplantation.
- Continued Overall Survival Benefit After 5 Years’ Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies...
- Differential Induction of Apoptosis in Human Leukemia Cells (ML-1, ML-2, CTV-1 and KASUMI-1) Exposed to the Proteasome Inhibitor Bortezomib and the Effect of Transforming Growth Factor-beta Signaling Pathway
- Double Transplantation with Melphalan (200 mg/m2) Compared with Triple Transplantation with Intermediate Dose Melphalan (100 mg/m2) in Patients with Multiple Myeloma
- Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391).
- Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391)
- EFFICACY OF LONG-TERM LENALIDOMIDE TREATMENT OF MM PATIENTS WITH AT LEAST ONE PRIOR THERAPY BASED ON CZECH LOCAL DATA
- Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up
- ELOQUENT-2: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LENALIDOMIDE/DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
- ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
- Evaluation of Current Clinical Models for Risk of Progression from Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma or Related Malignancies in 2028 Persons Followed in the Czech Republic
- EVALUATION OF CURRENT CLINICAL MODELS FOR RISK OF PROGRESSION FROM SMOLDERING MULTIPLE MYELOMA TO MULTIPLE MYELOMA IN 287 PATIENTS FOLLOWED IN THE CZECH REPUBLIC
- Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin with Bortezomib Alone in Subjects with Relapsed or Refractory Multiple Myeloma
- GAIN/AMPLIFICATION OF 1Q21 IS THE MOST POWERFUL GENETIC PROGNOSTIC FACTOR FOR PATIENTS TREATED BY AUTOLOGOUS STEM CELL TRANSPLANTATION
- I-FISH ANALYSIS OF IMMUNOFLUORESCENTLY LABELED PLASMA CELLS IN PATIENTS WITH MULTIPLE MYELOMA
- Komplexní změny karyotypu u pacientů s mnohočetným myelomem (MM)
- Lenalidomid (Revlimid) v léčbě mnohočetného myelomu – naše první zkušenosti
- LENALIDOMIDE-DEXAMETHASONE (LD) AS TREATMENT OF ACUTE CAST NEPHROPATHY-INDUCED RENAL FAILURE (ARF) IN MULTIPLE MYELOMA (MM). A PHASE II STUDY
- MMY-3002: A Phase 3 Study Comparing BortezomibMelphalanPrednisone (VMP) with MelphalanPrednisone (MP) in Newly Diagnosed Multiple Myeloma.
- MOLECULAR CYTOGENETIC STUDY OF IMMUNOFLUORESCENTLY LABELED PLASMA CELLS AND PROGNOSTIC SIGNIFICANCE OF CLONAL CHROMOSOMAL ABERRATIONS IN 208 PATIENS WITH MULTIPLE MYELOMA
- Molecular Cytogenetic Study of Immunofluorescently Labeled Plasma Cells and Prognostic Significance of Clonal Chromosomal Aberrations in Multiple Myeloma.
- ORAL MLN9708, AN INVESTIGATIONAL PROTEASOME INHIBITOR, IN COMBINATION WITH MELPHALAN AND PREDNISONE IN PATIENTS WITH PREVIOUSLY UNTREATED MULTIPLE MYELOMA: A PHASE 1 STUDY
- Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/refractory multiple myeloma.
- Prediction of Progression of Smouldering into Therapy Requiring Multiple Myeloma By Easily Accessible Clinical Factors [in 527 Patients]
- Preliminary Results of a Phase 2 Study of PD 0332991 in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma
- Prospective, Randomized Comparison between Double Transplantation (T) with Melphalan (200 mg/m2) and Triple T with Intermediate Dose Melphalan (100 mg/m2) in Patients with Multiple Myeloma (An Interim Analysis)
- RANDOMIZED PHASE 2 STUDY OF BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE WITH OR WITHOUT CYCLOPHOSPHAMIDE AS INDUCTION THERAPY IN PREVIOUSLY UNTREATED MULTIPLE MYELOMA (MM): LONG-TERM FOLLOW-UP RESULTS
- Randomized Placebo-Controlled Phase III Study Of Perifosine Combined With Bortezomib and Dexamethasone In Relapsed, Refractory Multiple Myeloma Patients Previously Treated With Bortezomib
- Registry of Monoclonal Gammopathies (RMG) in the Czech Republic
- Similar Efficacy of Thalidomide-Based and Bortezomib-Based Regimens In the First Relapse of 209 Multiple Myeloma Patients Previously Untreated with Novel Drugs
- Subcutaneous and Intravenous Bortezomib in Multiple Myeloma Patients Has Similar Response Rates and Toxicity Profile with No Difference in the Incidence of Peripheral Neuropathy: Report of the Czech Myeloma Group
- Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment and Thalidomide-Interferon vs. Interferon Maintenance Therapy in Elderly Patients with Multiple Myeloma.
- Thalidomide-Interferon Vs. Interferon Maintenance Therapy After Thal-Dex Vs. MP Induction Therapy in Elderly Patients with Multiple Myeloma
- THE RISK OF THROMBOCYTOPENIA AND NEUROPATHY AFTER BORTEZOMIB THERAPY DEPENDS ON THE BASELINE PLATELET COUNTS AND PREVIOUS NEUROPATHY RESULTS OF CZECH MYELOMA GROUP (CMG).
- Účinky bortezomibu na buněčné linie karcinomu prsu
- Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma
Články v Klinické onkologii
- Asymptomatický a léčbu vyžadující mnohočetný myelom – data z českého Registru monoklonálních gamapatií
- Léčba anakinrou u Schnitzler-syndromu-výsledky první retrospektivní multicentrické studie šesti pacientů z České republiky
- lnterleukin-6, tumor-nekrotizující faktor a jejich solubilní receptory u Bence-Jonesovy nefropatie - možná úloha v patogenezi a význam stanovení pro prognózu renální insuficience
- První zkušenosti s léčbou mnohočetného myelomu v České republice
- Příklady využití:Výsledky molekulárně cytogenetické analýzy imunofluorescenčně značených plasmatických buněk u pacientů s MM zařazených ve studii CMG 2002
- Účinnost a snášenlivost NOVOBANU (tropisentronu) v prevenci nevolnosti a zvracení u nemocných vysoce emetogenní chemoterapií (cisplatina, DTIC)
